

## Grifols celebrates 25<sup>th</sup> anniversary of its Diagnostic R&D center in Bizkaia, a key driver of its sector leadership

- *Grifols' center in Derio (Bizkaia) is currently developing cutting-edge platforms to reinforce its leadership in transfusion medicine and drive the company's expansion in clinical diagnostics*
- *The site has spurred major innovations, including a test to detect the SARS-CoV-2 virus and an oral swab to identify genetic risk for alpha<sub>1</sub>-antitrypsin deficiency (alpha-1)*
- *Basque institutions and healthcare sector representatives join the anniversary celebration, held at the Bizkaia Technology Park*

**Barcelona, Spain, May 29, 2025** - Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today celebrated the 25<sup>th</sup> anniversary of its Derio (Bizkaia) facility, a center specialized in the development of *in vitro* diagnostic systems. For more than two decades, the campus has contributed to improving patient outcomes and reinforcing the company's leadership in transfusion medicine.

The commemorative event was held at the Bizkaia Technology Park in Derio and was attended by several dignitaries, including Elixabete Etxanobe, General Deputy of Bizkaia; Mikel Jauregi, Basque Government Minister of Industry, Energy Transition and Sustainability; Esther Apraiz, Mayor of Derio; Ainara Basurko, Provincial Deputy for Economic Promotion; Jaione Ganzarain, Basque Government Deputy Minister of Technology, Innovation and Digital Transformation, and Ander Caballero, Secretary General for Foreign Action and Euskadi Global.

Grifols is a global leader in transfusion medicine. Each year, its solutions analyze tens of millions of blood and plasma samples to ensure they are pathogen-free and compatible between donor and recipient.

The Derio campus is currently developing next-generation platforms for the Diagnostic business unit that will enable Grifols to offer the three most widely used diagnostic technologies in transfusion medicine — molecular testing, immunoassays, and blood typing — in a fully automated format for blood banks and laboratories around the world. Grifols plans to launch new generations of these assays and technologies over the coming years.

In recent years, the company has expanded its presence in clinical diagnostics through the development of innovative technologies, enabling steady progress in the *in vitro* diagnostics (IVD) sector — an area in which the Derio center plays a fundamental role.

Founded in 2000 under the name Progenika and acquired by Grifols in 2013, the Derio research and manufacturing center has made significant contributions to the healthcare sector. In 2004, it launched the first CE-marked genetic test for familial hypercholesterolemia, followed in 2008 by its first blood genotyping product, now a standard in the field.

More recently, in 2020 and in record time, this Grifols center developed a highly sensitive molecular test to detect the SARS-CoV-2 virus, which was used in many hospitals across Spain during the global COVID-19 pandemic. Additionally, the Derio facility developed the AlphaID™ test, designed to detect the most prevalent variants associated with alpha<sub>1</sub>-antitrypsin deficiency (alpha-1), a leading cause of chronic obstructive pulmonary disease (COPD), a serious respiratory condition.

Grifols' expanding clinical diagnostics portfolio also includes the Promonitor® line of assays, which measure levels of biologic drugs and anti-drug antibodies in patients undergoing treatment for chronic inflammatory diseases and other conditions. These tests help monitor patients receiving biologic therapies, enabling dose adjustments and improving treatment effectiveness.

"Since the beginning, Grifols has been defined by its entrepreneurial and innovative spirit. We remain committed to innovation as a way to deliver better and more effective solutions for patients," said Nacho Abia, Grifols Chief Executive Officer. "Our Derio team has proven to be at the forefront of blood genotyping and, more recently, clinical diagnostics. They will continue to play a key role in the company's future."

## Diagnostic growth

Grifols' Diagnostic business unit grew by 5.2% in the first quarter of 2025 compared to the same period last year, reaching revenues of €170 million.

"As part of our five-year strategic plan, we are developing the diagnostic solutions of the future to enhance the safety and reliability of transfusions and improve the diagnosis of clinical conditions, ultimately contributing to a better quality of life for both patients and donors," said Antonio Martínez, President Diagnostic Business Unit. "We have a highly qualified and committed team that will help revolutionize disease diagnostics and transfusion health for the benefit of science and the patient community."

Today, more than 95 professionals work at the Derio facility, primarily focused on research and development of *in vitro* diagnostic solutions. In addition to R&D and the development and manufacturing of diagnostic tests, the campus also conducts patient sample analysis in therapeutic areas where Grifols operates.

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

## **MEDIA CONTACTS:**

### **Grifols Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

## **INVESTORS:**

### **Investors Relations & Sustainability**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

[sostenibilidad@grifols.com](mailto:sostenibilidad@grifols.com) – [sustainability@grifols.com](mailto:sustainability@grifols.com)

Tel. +34 93 571 02 21

## **LEGAL DISCLAIMER**

*The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.*